NCT04528680 2026-04-13
SC9/ABX
Northwestern University
Phase 1/2 Active not recruiting
Clinical Trials
10 trialsNCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT06483555 2026-04-01
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT05586516 2026-03-30
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
iOnctura
Phase 1/2 Completed
NCT06904378 2026-03-30
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Phase 1/2 Recruiting
NCT06953323 2026-03-27
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT04165070 2026-03-16
MK-3475-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT02705196 2026-02-24
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
Phase 1/2 Completed
NCT07281976 2026-02-12
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT06771622 2026-02-04
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Phase 1/2 Active not recruiting